Insiders who reported open-market trades in the last 12 months at the companies Reshma Kewalramani files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Jeffrey M. Leiden - $60.94M in VRTX purchases and sales in the last 12 months
Amit Sachdev - $28.38M in VRTX purchases and sales in the last 12 months
Carmen Bozic - $11.31M in VRTX purchases and sales in the last 12 months
Reshma Kewalramani is a corporate insider, tracked as CEO & President, Director of VERTEX PHARMACEUTICALS INC / MA (VRTX). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Reshma Kewalramani last file a Form 4?
The most recent primary Form 4 on record is dated 3 March 2026, one of 8 filings going back to 2024.
Has Reshma Kewalramani been buying or selling stock?
Recorded transactions: 2 open-market purchases ($3.90M) and 14 open-market sales ($27.57M) across all tracked filings.
Reshma Kewalramani is CEO & President, Director of VERTEX PHARMACEUTICALS INC / MA (VRTX). 8 SEC Form 4 filings on record going back to 2024, most recently on 3 March 2026. Most recent open-market trade: sold $857K of VRTX on 3 March 2026. Lifetime open-market purchases: $3.90M. Lifetime open-market sales: $27.57M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Reshma Kewalramani.
InsiderAlpha's records for Reshma Kewalramani go back to 2024: 8 primary Form 4 filings, an average of 2.7 per year. The typical open-market purchase is $1.95M (2 buys totaling $3.90M). The largest single buy on record is $2.23M of VRTX in 2025. Sales side: 14 recorded sales totaling $27.57M, so the filing history runs sell-heavy by dollar value. 14 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
